UY31507A1 - PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS - Google Patents

PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS

Info

Publication number
UY31507A1
UY31507A1 UY31507A UY31507A UY31507A1 UY 31507 A1 UY31507 A1 UY 31507A1 UY 31507 A UY31507 A UY 31507A UY 31507 A UY31507 A UY 31507A UY 31507 A1 UY31507 A1 UY 31507A1
Authority
UY
Uruguay
Prior art keywords
guanilate
activators
cycling
alkyl
derivatives soluble
Prior art date
Application number
UY31507A
Other languages
Spanish (es)
Inventor
Olivier Mirguet
Francoise Jeanne Gellibert
Nerina Dodic
Anne Marie Jeanne Bouillot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0723629A external-priority patent/GB0723629D0/en
Priority claimed from GB0813714A external-priority patent/GB0813714D0/en
Priority claimed from GB0816960A external-priority patent/GB0816960D0/en
Application filed filed Critical
Publication of UY31507A1 publication Critical patent/UY31507A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Se desriben compuestos de formula (I) donde R1 y R2 son independientemente seleccionados de hidrogeno, halo, CF3, C1-4 alquilo y alilo; Donde R3 representa CF3 o C1-4 alquilo y R3a representa CF3 O C1-4 alquilo; R4 representa hidrogeno o metilo; Z está ausente o representa (CH2)2, O o CCH2 A y X son como se definen o sales del mmismo los cuales activan la guanilato ciclasa soluble (sGC), composiciones farmacéuticamente aceptables conteniendo los mismos, su uso en medicina y el proceso para su preparacion.Compounds of formula (I) where R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4 alkyl and allyl are described; Where R3 represents CF3 or C1-4 alkyl and R3a represents CF3 O C1-4 alkyl; R4 represents hydrogen or methyl; Z is absent or represents (CH2) 2, O or CCH2 A and X are as defined or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutically acceptable compositions containing them, their use in medicine and the process for its preparation.

UY31507A 2007-12-03 2008-12-01 PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS UY31507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723629A GB0723629D0 (en) 2007-12-03 2007-12-03 Compounds
GB0813714A GB0813714D0 (en) 2008-07-25 2008-07-25 Compounds
GB0816960A GB0816960D0 (en) 2008-09-16 2008-09-16 Compounds

Publications (1)

Publication Number Publication Date
UY31507A1 true UY31507A1 (en) 2009-07-17

Family

ID=40717321

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31507A UY31507A1 (en) 2007-12-03 2008-12-01 PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS

Country Status (5)

Country Link
AR (1) AR069517A1 (en)
PE (1) PE20091258A1 (en)
TW (1) TW200938529A (en)
UY (1) UY31507A1 (en)
WO (1) WO2009071504A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070339A1 (en) 2007-09-06 2010-10-29 Мерк Шарп Энд Домэ Корп. ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
US8410277B2 (en) 2007-12-26 2013-04-02 Eisai R&D Managment Co., Ltd. Method for manufacturing heterocycle substituted pyridine derivatives
US8461348B2 (en) 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX342944B (en) * 2010-02-05 2016-10-18 Adverio Pharma Gmbh sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS.
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
MX2012013574A (en) 2010-05-26 2013-01-24 Bayer Ip Gmbh THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
EP2585055A1 (en) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
JP5715713B2 (en) * 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Soluble guanylate cyclase activator
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
EP2766360B1 (en) 2011-08-12 2017-07-12 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
JP6118965B2 (en) 2012-04-16 2017-04-26 トーアエイヨー株式会社 Bicyclic compound
MA37891B1 (en) * 2012-09-07 2018-05-31 Boehringer Ingelheim Int Alcoxypyrazoles as activators of soluble guanylate cyclase
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
RU2016112542A (en) 2013-09-05 2017-10-06 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед NEW ACTIVATORS OF SOLUBLE GUANILATICYCLASE AND THEIR APPLICATION
CA2927420A1 (en) 2013-10-15 2015-04-23 Toa Eiyo Ltd. 4-aminomethylbenzoic acid derivative
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
TW201625601A (en) * 2014-07-02 2016-07-16 諾華公司 Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
TW201625584A (en) 2014-07-02 2016-07-16 諾華公司 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW201625586A (en) 2014-07-02 2016-07-16 諾華公司 Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
EA032972B1 (en) 2014-07-22 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CN105980373A (en) * 2014-09-05 2016-09-28 葛兰素史密斯克莱知识产权发展有限公司 Novel soluble guanylate cyclase activators and their use
JP6678656B2 (en) * 2014-09-19 2020-04-08 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Novel soluble guanylate cyclase activators and their use
CA2984983A1 (en) 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
LT3325013T (en) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof
WO2017103888A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
EP3525778A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2018153899A1 (en) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3787610A1 (en) 2018-04-30 2021-03-10 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN111423353B (en) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 Polysubstituted N-arylpyrrole compound and preparation method thereof
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase

Also Published As

Publication number Publication date
AR069517A1 (en) 2010-01-27
PE20091258A1 (en) 2009-09-12
WO2009071504A1 (en) 2009-06-11
TW200938529A (en) 2009-09-16

Similar Documents

Publication Publication Date Title
UY31507A1 (en) PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS
HRP20110445T1 (en) Bisadenosine compounds as adenosine a2a receptor agonists
UY29393A1 (en) NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
EA200901379A1 (en) DERIVATIVES OF NICOTINIC ACID AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS 5 SUBTILES
EA200970585A1 (en) BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
ES2317335T3 (en) DERIVATIVES OF PHENYLPIPERAZINE WITH A COMBINATION OF DOPAMINE-D2 RECEPTOR PARTIAL AGONISM AND INHIBITION OF SEROTONINE RECAPTATION.
UY31546A1 (en) BIS- (SULFONYLAMINE) DERIVATIVES IN THERAPY 205
UY29825A1 (en) SUBSTITUTED DERIVATIVES OF 3H-IMIDAZOL- (4.5 B (BETA)) PIRIDINA-2-IL BENZOATES AND BENZAMIDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
BR0214675A (en) Novel compounds and their use in medicine, processes for their preparation and pharmaceutical compositions containing them
MXPA05011710A (en) Fused pyrimidine derivatives with crf activity.
CY1113873T1 (en) HYDROXYBENZAMIDE DERIVATIVES AS HSP90 SUPPORTING AGENTS
PE20140968A1 (en) SUBSTITUTED BENZAMIDE DERIVATIVES
CO5590895A2 (en) DERIVATIVES OF SULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS
UY29312A1 (en) PIPERAZIN-1-CARBOXAMIDAS N, 4, SUBSTITUTES AND THEIR DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
ATE507212T1 (en) MORPHOLINES AS 5HT2C AGONISTS
AR029821A1 (en) DECAHIDRO-ISOQUINOLINAS, A PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
AR063028A1 (en) HETEROCICLIC DERIVATIVES OF PIRIDIN-2-CARBOXAMIDE GLUCOKINASE ACTIVATORS, USEFUL FOR THE TREATMENT OF DIABETES AND OBESITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
UY29896A1 (en) NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
ATE502936T1 (en) 2, 6-DI-(HETERO-)ARYL-4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
NO20062491L (en) Benzoxazine derivatives and their use
UA86836C2 (en) Isoxazoline derivatives, process for the preparation thereof (variants) and their use as herbicides
UY29739A1 (en) DERIVATIVES OF AMIDAS OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PROCESSES OF PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND APPLICATIONS
AR072904A1 (en) PHENYLAMINE-ISONICOTINAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM